1. Alderman M, Aiyer KJV. Uric Acid: Role in Cardiovascular Disease and Effects of Losartan. Curr Med Res Opin 2004; 20: 369–379.
2. Feig DI, Kang DH, Johnson RJ. Uric Acid and Cardiovascular Risk. N Engl J Med 2008; 359: 1811–1821.
3. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
4. Vasan RS, Sullivan LM, Wilson PW et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142: 393–402.
5. Wilson PWF. Overview of the risk factors for cardiovascular disease. UpToDate® 2009 (version 17.1). [http://www.uptodate.com/patients/content/topic.do?topicKey=~QGsob5Yuvb].
6. Lippi G, Montagnana M, Franchini M et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1–7.
7. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008; 75 (Suppl 5): S13–S16.
8. Freedman DS, Williamson DF, Gunter EW et al. Relation of aserum uric acid to mortality ischemic heart disease: the NHANES I Epidemiologic Follow‑up Study. Am J Epidemiol 1995; 141: 637–644.
9. Moriarity JT, Folsom AR, Iribarren C et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–143.
10. Verdecchia P, Schillaci G, Reboldi G et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072–1078.
11. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I Epidemiologic Follow‑up Study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404–2410.
12. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.
13. Ward HJ. Uric acid as a independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670–671.
14. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998; 16: 761–769.
15. Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–1154.
16. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991–1997.
17. Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89: 12–17.
18. Short RA, Johnson RJ, Tuttle KR. Uric Acid, Microalbuminuria and Cardiovascular Events in High‑Risk Patients. Am J Nephrology 2005; 25: 36–44.
19. Bos MJ, Koudstaal PJ, Hofman A et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006; 37: 1503–1507.
20. Lehto S, Niskanen L, Rönnemaa T et al. Serum uric acid is a strong predictor of stroke in patients with non‑insulin‑dependent diabetes mellitus. Stroke 1998; 29: 635–639.
21. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101–1106.
22. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure‑independent mechanism. Am J Physiol Renal Physiol 2002; 82: F991–F997.
23. Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281–287.
24. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355–360.
25. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924–932.
26. Feig DI, Johnson RJ. Hyperuricemia in child-hood primary hypertension. Hypertension 2003; 42: 247–252.
27. Brand FN, McGee DL, Kannel WB et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985; 121: 11–18.
28. Nakanishi N, Okamoto M, Yoshida H et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523–530.
29. Alper AB jr, Chen W, Yau L et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45: 34–38.
30. Masuo K, Kawaguchi H, Mikami H et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474–480.
31. Nagahama K, Inoue T, Iseki K et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835–841.
32. Sundström J, Sullivan L, D’Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33.
33. Perlstein TS, Gumieniak O, Williams GH et al. Uric acid and the development of Hypertension: the Normative Aging Study. Hypertension 2006; 48: 1031–1036.
34. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006; 24: 621–626.
35. Puig JG, Martínez MA, Mora M et al. Serum urate, Metabolic Syndrome, and Cardiovascular Risk Factors: A Population-Based Study. Nucleos Nucleot Nucl Acids 2008; 27: 620–623.
36. Puig JG, Martínez MA. Hyperuricemia, gout, and the metabolic syndrome: serum urate and the metabolic syndrome. Curr Opin Rheumatol 2008; 20: 187–191.
37. Hjortnaes J, Algra A, Olijhoek J et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol 2007; 34: 1882–1887.
38. Choi HK, Ford ES, Li C et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109–115.
39. Strazzullo P, Barbato A, Galletti F et al. Abnormalities of renal sodium handling in the metabolic syndrome: results of the Olivetti Heart Study. J Hypertens 2006; 24: 1633–1639.
40. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk. Nutr Metab Cardiovasc Dis 2007; 17: 409–414.
41. Nakagawa T, Tuttle K, Short RA et al. Hypothesis: fructose‑induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1: 80–86.
42. Nakagawa T, Mazzali M, Kang DH et al. Hyperuricemia cause glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2–7.
43. Kang DH, Nakagawa T, Feng L et al. A role of uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888–2897.
44. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25: 43–49.
45. Nakagawa T, Mazzali M, Kang HD et al. Uric acid: A uremic toxin? Blood Purif 2006; 24: 67–70.
46. Sánchez-Lozada LG, Tapia E, Avila-Casado C et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283: F1105–F1110.
47. Kang DH, Park SK, Lee IK et al. Uric acid‑induced C‑reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553–3562.
48. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein‑1 production in vascular smooth Musile cells via mitogen‑activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287–1293.
49. Tomita M, Mizuno S, Yamanaka H et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403–409.
50. Iseki K, Ikemiya Y, Inoue T et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642–650.
51. Obermayr RP, Temml C, Gutjahr G et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407–2413.
52. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2007; 18: 287–292.
53. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end‑stage renal disease: 25-year follow‑up. Arch Intern Med 2009; 169: 342–350.
54. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34–42.
55. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27: 435–440.
56. Sturm G, Kollerits B, Neyer U et al. Uric acid as a risk factor for progression of non‑diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exper Gerontol 2008; 43: 347–352.
57. Mazzali M. Uric acid and transplantation. Semin Nephrol 2005; 25: 50–55.
58. Toprak O, Cirit M, Esi E et al. Hyperuricemia as a risk factor for contrast‑induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv 2006; 67: 227–235.
59. Ruilope LM. The renal effects of losartan. Recep Cardiovasc Dis 1998; 5: 1–3.
60. Baker JF, Krishnan E, Chen L et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118: 816–826.
61. Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 2005; 11: 4125–4132.
62. Krishnan E, Baker JF, Furst DE et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688–2696.
63. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894–900.
64. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51–59.